A new molecular assay detecting toxigenic Clostridium difficile, the BD Max Cdiff (Becton, Dickinson), was evaluated with 360 diarrheal feces samples. It exhibited high sensitivity (97.7%) and specificity (99.7%). The positive (97.7%) and negative (99.7%) predictive values of this test allow an accurate answer within 2 h.
T
oxigenic Clostridium difficile is the most common cause of hospital-acquired diarrhea. Toxins A and B are the main virulence factors responsible for the clinical symptoms. Detection of toxigenic C. difficile by conventional bacteriology (culture) is difficult and time-consuming, although an accurate early diagnostic of Clostridium difficile infection (CDI) is necessary to implement infection control procedures and treat patients as soon as possible. The most commonly used laboratory tests that target these toxins are commercial enzyme immunoassays (EIA) performed directly on stool samples with a low turnaround time. To validate these EIA, two gold standards were used in previous studies: cell culture neutralization assay (CCNA) and toxigenic culture (TC). This led to wide variations in the EIA performances reported in the literature. Membrane-type EIA had a mean sensitivity and specificity of 72% and 98%, respectively, when CCNA was used as a gold standard. Their sensitivity and specificity were evaluated at 52% and 98% when the reference was TC, which is a more sensitive method for CDI diagnosis (4) .
Nucleic acid amplification tests (NAATs) were then developed with the objective of delivering results as fast as EIA while being more accurate. They often target the toxin B gene (tcdB), which is specific for toxigenic C. difficile (1) . In-house PCR methods were quickly followed by commercial assays for greater ease of use by all kinds of laboratories. NAAT performances were thoroughly investigated in a recent meta-analysis: mean sensitivity and specificity were estimated at 90% and 96%, respectively, against TC (5).
In our study, two molecular assays, the new BD Max Cdiff (Becton, Dickinson, Franklin Lakes, NJ) and the BD GeneOhm Cdiff, were evaluated against EIA followed by toxigenic culture, which is the approach used routinely in our laboratory.
Three hundred sixty diarrheal stool specimens were prospectively collected from inpatients at the Lille University Hospital from January to February 2012. Criteria for rejection included formed stools or a duplicate specimen submitted during the last 7 days. Stool samples were stored at 4°C and tested less than 24 h after their arrival by EIA, toxigenic culture, and BD GeneOhm Cdiff performed in parallel with the new test BD Max Cdiff. An aliquot was also stored at Ϫ20°C for later testing if necessary. Toxigenic culture was performed after an alcoholic shock (2) and isolation of 100 l on cycloserine cefoxitin fructose agar (CCFA) medium followed by a 48-h anaerobic incubation. Colonies suspected of being C. difficile based on morphology were identified by MALDI-TOF (matrix-assisted laser desorption ionization-time of flight) mass spectrometry (Bruker Daltonics, Wissembourg, France) (8) . As CCNA was not available in our laboratory, all strains of C. difficile isolated in culture were tested for the tcdB gene with the BD GeneOhm, which was our reference method.
The BD Max and BD GeneOhm assays target the same tcdB sequence. The BD Max Cdiff assay was performed as follows. Ten microliters of stool was collected with a sterile loop and transferred to a BD Max sample buffer tube, which was then vortexed for 10 s. The automated extraction procedure uses achromopeptidase, an enzyme exhibiting strong bacteriolytic activity against Gram-positive bacteria (7) . After 50 to 90 min of extraction (depending on the number of samples), the eluate was automatically added to a master mix and inserted into 4-l chambers. Real-time PCR was completed in less than 30 min (45 cycles of 30.3 s) in a microfluidic chamber system, which allowed fast temperature variations. The BD GeneOhm assay was performed as described elsewhere (13) . These two PCR assays used an internal control to validate each experiment. We used the Wampole Tox A/B Quick Check (Alere, Orlando, FL) for EIA testing according to the manufacturer's instructions.
C. difficile was isolated in culture from 54 stool samples (15%). Among these, 44 (12.2%) possessed the tcdB gene according to the BD GeneOhm assay and were considered toxigenic strains. Table 1 highlights the results obtained for the 360 diarrheal stool samples.
The Wampole Tox A/B Quick Check used in this study presented a low sensitivity (43.2%). This particular EIA sensitivity was estimated at 84% compared with CCNA or TC (10), but more recently Eastwood et al. tested 600 stool samples and reported a sensitivity of 74% compared with TC (6). Finally, Tenover (12) and Peterson et al. (9) showed a low sensitivity of EIAs (from 40% to 60%) against TC. Overall, EIAs should not be used as standalone tests for toxigenic C. difficile detection, because their negative predictive value (NPV) is not high enough: a false-negative result can lead to misdiagnosis of a potentially life-threatening disease.
The BD Max Cdiff and the BD GeneOhm Cdiff assays exhibited higher sensitivities (97.7% and 95.4%, respectively) and NPVs greater than 99%. The observed differences between these two methods were not statistically significant (P ϭ 1.00 using the McNemar test). The main advantage of the BD Max assay over BD GeneOhm is the automation of the extraction and amplification steps: the hands-on time necessary to process 10 stool samples was about 10 min for BD Max, versus 40 min for BD GeneOhm ( Table  2) . Cycle thresholds (C T ) of positive results were also lower with the BD Max Cdiff assay (median ϭ 23.6) than with BD GeneOhm (median ϭ 33.0). The inhibition rate for the BD Max Cdiff assay was 3.8%, but all the PCR-inhibiting samples were successfully analyzed after one freeze-thaw cycle.
NAATs may be used as first-line tests on diarrheal stool specimens when CDI is suspected. A negative result allows CDI to be quickly ruled out. In case of a positive result, high accuracy can reduce any delay in starting specific CDI treatment. If an outbreak is suspected, positive stool samples may then be cultured to perform epidemiological typing. Several laboratories have adopted a two-step algorithm based on a first sensitive test (detection of glutamate dehydrogenase) with a very high NPV followed by a confirmatory test, which could be a NAAT (14) . However, the sensitivity of glutamate dehydrogenase assays was reported to be only about 85% in a recent publication (9) , which impairs the value of these algorithms.
One of the limitations of this work is the potential for NAATs and TC to detect colonization with toxin-producing C. difficile and lead to a wrong diagnosis of CDI. Therefore, it is crucial to rule out obvious causes of diarrhea before using NAATs for CDI diagnosis. Even then, it is possible that diarrhea was due to other enteric pathogens in some of the EIA-negative TC-positive cases. Regarding our reference method, reported sensitivities of the evaluated assays would probably have been lower if we had used a broth enrichment to enhance C. difficile recovery. TC has not yet been standardized, and its performance varies depending on the composition of CCFA medium, the use of broth enrichment, and the use of ethanol or heat shock pretreatment. CCNA or PCR may be used to determine whether the isolated strain produces toxins or possesses toxin-related genes (3); EIA is unreliable in this indication (11) . Comparing studies using different gold standards (TC or CCNA) is difficult, but even studies using different versions of TC will yield different results.
In conclusion, the two molecular assays evaluated correlates well with the presence of tcdB-positive C. difficile in a stool specimen. The new BD Max assay is a rapid and completely automated method exhibiting excellent diagnosis performances. 
